Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516570 | 0.80 | POLB (0.41) | POLBMAPTGRM1KMT2ANPSR1 | |
| SCHEMBL5438823 | 0.80 | POLB (0.56) | POLBMAPTTP53KMT2AMEN1 | |
| SCHEMBL5431417 | 0.80 | POLB (0.40) | POLBMAPTGRM1KMT2ANPSR1 | |
| SCHEMBL4756615 | 0.79 | KMT2A (0.41) | MAPTTP53HTR6PTGS2KMT2A | |
| SCHEMBL4083046 | 0.78 | POLB (0.46) | POLBMAPTGRM1KMT2ANPSR1 | |
| SCHEMBL5431768 | 0.78 | ALDH1A2 (0.42) | POLBMAPTTP53KMT2AMEN1 | |
| SCHEMBL5437892 | 0.78 | ALDH1A3 (0.60) | POLBMAPTTP53KMT2AMEN1 | |
| SCHEMBL1992040 | 0.76 | POLB (0.51) | POLBMAPTGRM1KMT2ANPSR1 | |
| SCHEMBL5432487 | 0.76 | KDM1A (0.43) | PTGS2KMT2ANPSR1 | |
| SCHEMBL5429219 | 0.74 | ALDH1A2 (0.40) | FADS1MAPTTP53HTR6PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | claimed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | POLB 4218/4885FADS1 2383/4885TGM2 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.